Results 131 to 140 of about 1,026 (172)

Bulevirtide and Emerging Drugs for the Treatment of Hepatitis D

Expert Opinion on Biological Therapy, 2023
Hepatitis delta virus (HDV) causes acute and chronic liver disease that requires the co-infection of the Hepatitis B virus and can lead to significant morbidity and mortality. Bulevirtide is a recently introduced entry inhibitor drug that acts on the sodium taurocholate cotransporting peptide, thereby preventing viral entry to target cells in chronic ...
Steven-Huy Han
exaly   +3 more sources

Bulevirtide for patients with compensated chronic hepatitis delta: A review

Liver International, 2022
AbstractChronic hepatitis delta (CHD) affects approximately 10–20 million people worldwide and represents the most severe form of chronic viral hepatitis, as it is characterized by high rates of progression to cirrhosis and its complications (end‐stage liver disease, hepatocellular carcinoma). In the last 30 years, the only treatment option for CHD has
Elisabetta Degasperi, Maria Paola Anolli, Pietro Lampertico   +2 more
openaire   +4 more sources

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D [PDF]

New England Journal of Medicine, 2023
Background: Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into hepatocytes.
Antje Blank, John Flaherty, Annemarie Berger   +2 more
exaly   +3 more sources

Bulevirtide for HBV and HDV infections

Drugs of Today, 2021
Hepatitis B virus (HBV) and its satellite virus hepatitis D (HDV) are common worldwide hepatotrophic infections responsible for cirrhosis and hepatocellular carcinoma (HCC). The more common HBV infection has several therapeutic regimens currently available for suppression of viral replication.
D, Yardeni, C, Koh
openaire   +2 more sources

Bulevirtide: First Approval

Drugs, 2020
Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated ...
Connie, Kang, Yahiya Y, Syed
openaire   +2 more sources

Patient-Reported Outcomes in Chronic Hepatitis Delta: An Exploratory Analysis of the Phase III MYR301 Trial of Bulevirtide [PDF]

Journal of Hepatology
Background & Aims: Once-daily treatment of chronic hepatitis delta (CHD) with bulevirtide is well tolerated and associated with significant reductions in HDV RNA in the blood and in biochemical liver disease activity.
Tatyana Stepanova, Vithika Suri, Tatiana Stepanova   +2 more
exaly   +4 more sources

Real-World Effectiveness and Safety of Bulevirtide Monotherapy for Up to 96 Weeks in Patients With HDV-Related Cirrhosis

Journal of Hepatology
Background & Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for the treatment of compensated chronic HDV infection; however, real-world data in large cohorts of patients with cirrhosis are lacking.
Adriano Pellicelli, Nicola Coppola, Frank Tacke   +2 more
exaly   +4 more sources

Bulevirtide Monotherapy in Patients With Chronic HDV: Efficacy and Safety Results Through Week 96 From a Phase III Randomized Trial [PDF]

Journal of Hepatology
Background & Aims: Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed treatment at week (W) 48, the primary efficacy endpoint, in the ...
Antje Blank, Annemarie Berger, Markus Cornberg   +2 more
exaly   +2 more sources

Bulevirtide in chronic hepatitis D: a profile of its use

Drugs & Therapy Perspectives, 2021
Bulevirtide (HEPCLUDEX®), a first-in-class entry inhibitor, is a new option for the treatment of chronic hepatitis D, caused by hepatitis delta virus (HDV) infection, in HDV-RNA positive adults with compensated liver disease. In a pivotal phase IIb trial in patients with chronic hepatitis D, treatment with bulevirtide in combination with tenofovir ...
openaire   +1 more source

Bulevirtide

Reactions Weekly, 2023
openaire   +2 more sources